Archived Messages From the President
July 18th, 2016
Our last email was a survey asking your opinions on safety issues with medicines. Obamacare created a shortcut for approval for biosimilars a drug that will be a competitor to the biologic that was originally approved. These biologics are life changing medicines for diseases like Rheumatoid Arthritis and Psoriasis. While RetireSafe looks forward to the promise of savings in biosimilars we have concerns that the short cut has allowed the Food and Drug Administration (FDA) to cut corners and ignore some safety measures concerning biosimilars.
If you have not had a chance to take the survey…
See the results of the survey so far…
Your answers and comments left no doubt that these safety issues were important to you. Having this input was especially important because RetireSafe was scheduled to testify at the FDA as they considered approving two more of these biosimilars and we wanted to use the results of the survey to tell the FDA how you felt about these safety questions. You told us . . . and we testified at the FDA on July 12th and 13th.
You can read the testimony from the 13th here and click below to watch the video.
It was powerful to be able to relay the opinions of almost 700 of you directly to this agency that controls the safety of America’s medicines.
Your voice was heard. We appreciate your willingness to give us your opinion. Please feel free to reply to our emails anytime and tell us how you feel.